To compare flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis.
Interest no.2); the mean duration of follow-up; the stage of hepatic encephalopathy; inclusion criteria for the participants; duration and dosage of flumazenil; washout period between the two treatment periods; end points; evaluation criteria; use of placebo; and blindness of the study.
Methods of synthesis
How were the studies combined? A meta-analysis was performed according to a predetermined protocol based on the recommendations of Sacks et al. (see Other Publications of Related Interest no.3). All analyses were performed according to the intention-to-treat method.
For each end point, treatment efficacy was assessed by the Peto method (fixed-effect model; see Other Publications of Related Interest no.4) and the DerSimonian and Laird method (random-effects model; see Other Publications of Related Interest no.5). For crossover RCTs, the meta-analysis was performed using first-phase data, and a sensitivity analysis was carried out including the two treatment periods.
The pooled odds ratios (ORs; Peto method) and mean rate differences (DerSimonian and Laird method) were estimated for each study, along with the 95% confidence intervals (CIs).
How were differences between studies investigated?
Combinability was assessed using the following approaches: a comparison of each end point improvement in control groups by the chi-squared test, and heterogeneity tests (DerSimonian and Laird, and Peto methods).
Results of the review
Six RCTs (2 parallel and 4 crossover) and a total of 641 participants were included in the meta-analysis.
The total scores for methodological quality ranged from 19 to 26.
Clinical improvement.
First-phase data only (5 RCTs, n=623): the mean percentages of patients with clinical improvement were 27% in the treated groups and 3% in the placebo groups. Both methods showed the difference to be significant in favour of flumazenil: the OR was 6.15 (95% CI: 4.0, 9.5, p<0.001) when using Peto's method, while the mean rate difference was 28.6% (95% CI: 16.7, 40.5, p<0.001) without significant heterogeneity when using DerSimonian and Laird's method. Sensitivity analysis including second period of crossover studies (6 RCTs, n=1, 205) : the mean percentages of patients with clinical improvement were 19% in the treated groups and 2% in the placebo groups. Both methods showed the difference to be significant in favour of flumazenil: the OR was 5.50 (95% CI: 3.8, 7.9, p<0.001) when using Peto's method, while the mean rate difference was 30.9% (95% CI: 14.3, 47.5, p<0.001) without significant heterogeneity when using DerSimonian and Laird's method.
EEG improvement.
First-phase data only (3 RCTs, n=577): the mean percentages of patients with EEG improvement were 35% in the treated groups and 6% in the placebo groups. The Peto method showed the difference to be significant in favour of flumazenil (OR 5.8, 95% CI: 3.4, 9.7, p<0 .001), whereas the DerSimonian and Laird method did not. Sensitivity analysis including second period of crossover studies (5 RCTs, n=1,180): the mean percentages of patients with EEG improvement were 25% in the treated groups and 4% in the placebo groups. Both methods showed the difference to be significant in favour of flumazenil: the OR was 5.2 (95% CI: 3.7, 7.1, p<0.001) when using Peto's method, while the mean rate difference was 21.8% (95% CI: 5.2, 38.4, p<0.01) when using DerSimonian and Laird's method.
